HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m.
Provides Update on Performance Against Previously Announced Strategic Plan HOLLISTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to
Implemented significant cost reductions to offset Covid-19 impact on operating income HOLLISTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months ended March 31, 2020.
HOLLISTON, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2020 before the market opens on May 5, 2020, and will hold a conference call to discuss the results on May 5, 2020 at 8:00 a.m.
Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders HOLLISTON, Mass. , April 06, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Susan Steele has been appointed to the Company’s Board of Directors as a Class III director,
Company will continue to manufacture and ship innovative products for global development and research throughout crisis HOLLISTON, Mass. , March 23, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) has launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) –
Substantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets HOLLISTON, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline issued earlier today by Harvard Bioscience, Inc.
HOLLISTON, Mass. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2019 before the market opens on February 26, 2020 , and will hold a conference call to discuss the results on February 26, 2020 at
HOLLISTON, Mass. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green , Chairman, President and CEO, and Michael Rossi , CFO will attend The Benchmark Company’s 8th Annual Discovery One-on-One Conference to be held on December 4, 2019 at the
Improves adjusted operating margins while taking actions to underpin next year’s profit and growth targets Q3 Revenue of $27.4 million Q3 Operating Loss (GAAP) of $(1.4) million ; Adjusted Operating Income (Non-GAAP) of $3.3 million Q3 GAAP EPS of $(0.07) ; Adjusted Diluted EPS (Non-GAAP) of $0.04
